Patents by Inventor Winfried S. Wels

Winfried S. Wels has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Optimized DNA sequence of an antibody to improve quality and yield of bacterially expressed antibody fusion proteins
    Patent number: 8530637
    Abstract: Object matter of the invention is an optimized DNA sequence encoding the scFv(FRP5) antibody fragment. This novel sequence prevents the generation of the undesired by-product in the context of an scFv(FRP5)-ETA fusion protein, and possibly also other bacterially expressed scFv(FRP5)-containing fusion proteins. The DNA sequence of the scFv(FRP5) domain of scFv(FRP5)-ETA was modified by exchanging a distinct codon, thereby preventing an otherwise possible internal start of protein translation.
    Type: Grant
    Filed: January 6, 2011
    Date of Patent: September 10, 2013
    Assignee: Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus
    Inventors: Winfried S. Wels, Benjamin Daelken, Sylvia E. Schwarz
  • Optimized DNA Sequence Of An Antibody To Improve Quality And Yield Of Bacterially Expressed Antibody Fusion Proteins
    Publication number: 20110105742
    Abstract: Object matter of the invention is an optimized DNA sequence encoding the scFv(FRP5) antibody fragment. This novel sequence prevents the generation of the undesired by-product in the context of an scFv(FRP5)-ETA fusion protein, and possibly also other bacterially expressed scFv(FRP5)-containing fusion proteins. The DNA sequence of the scFv(FRP5) domain of scFv(FRP5)-ETA was modified by exchanging a distinct codon, thereby preventing an otherwise possible internal start of protein translation.
    Type: Application
    Filed: January 6, 2011
    Publication date: May 5, 2011
    Applicant: TopoTarget Germany AG
    Inventors: Winfried S. WELS, Benjamin Daelken, Sylvia E. Schwarz
  • Optimized DNA and protein sequence of an antibody to improve quality and yield of bacterially expressed antibody fusion proteins
    Patent number: 7887801
    Abstract: Object matter of the invention is an optimized DNA sequence encoding the scFv(FRP5) antibody fragment. This novel sequence prevents the generation of the undesired by-product in the context of an scFv(FRP5)-ETA fusion protein, and possibly also other bacterially expressed scFv(FRP5)-containing fusion proteins. The DNA sequence of the scFv(FRP5) domain of scFv(FRP5)-ETA was modified by exchanging a distinct codon, thereby preventing an otherwise possible internal start of protein translation.
    Type: Grant
    Filed: July 10, 2008
    Date of Patent: February 15, 2011
    Assignee: Topotarget Germany AG
    Inventors: Winfried S. Wels, Benjamin Daelken, Sylvia E. Schwarz
  • OPTIMIZED DNA AND PROTEIN SEQUENCE OF AN ANTIBODY TO IMPROVE QUALITY AND YIELD OF BACTERIALLY EXPRESSED ANTIBODY FUSION PROTEINS
    Publication number: 20090018079
    Abstract: Object matter of the invention is an optimized DNA sequence encoding the scFv(FRP5) antibody fragment. This novel sequence prevents the generation of the undesired by-product in the context of an scFv(FRP5)-ETA fusion protein, and possibly also other bacterially expressed scFv(FRP5)-containing fusion proteins. The DNA sequence of the scFv(FRP5) domain of scFv(FRP5)-ETA was modified by exchanging a distinct codon, thereby preventing an otherwise possible internal start of protein translation.
    Type: Application
    Filed: July 10, 2008
    Publication date: January 15, 2009
    Inventors: Winfried S. WELS, Benjamin Daelken, Sylvia E. Schwarz
  • Epidermal growth factor receptor antibodies
    Patent number: 6129915
    Abstract: The present invention is related to single and double chain antibodies to EGF receptor. The invention also relates to toxin conjugates of such antibodies. These antibodies are useful for treating and diagnosing the status of pathological conditions such as cancer and cellular hyper proliferation.
    Type: Grant
    Filed: April 23, 1999
    Date of Patent: October 10, 2000
    Assignee: Schering Aktiengesellschaft
    Inventors: Winfried S. Wels, Mathias Schmidt, Evangelia Vakalopoulou, Douglas W. Schneider
  • Growth factor receptor antibodies
    Patent number: 5942602
    Abstract: The present invention is related to single and double chain antibodies to EGF receptor. The invention also relates to toxin conjugates of such antibodies. These antibodies are useful for treating and diagnosing the status of pathological conditions such as cancer and cellular hyper proliferation.
    Type: Grant
    Filed: February 13, 1997
    Date of Patent: August 24, 1999
    Assignee: Schering Aktiengessellschaft
    Inventors: Winfried S. Wels, Mathias Schmidt, Evangelia Vakalopoulou, Douglas W Schneider
  • Recombinant antibodies specific for a growth factor receptor
    Patent number: 5571894
    Abstract: The invention concerns recombinant antibodies directed to the extracellular domain of the human growth factor receptor c-erbB-2 comprising a light chain variable domain and a heavy chain variable domain of a monoclonal antibody, monoclonal antibodies directed to c-erbB-2 themselves, a method of manufacturing those recombinant and monoclonal antibodies, hybridoma cells secreting those monoclonal antibodies, a method of manufacturing those hybridoma cells, DNAs encoding the heavy and light chain variable domains and the recombinant antibody, a method of manufacturing that DNA, hybrid vectors suitable for the expression of that DNA, host cells transformed with that DNA, and processes of using those recombinant and monoclonal antibodies in the diagnosis and treatment of tumors.
    Type: Grant
    Filed: April 29, 1994
    Date of Patent: November 5, 1996
    Assignee: Ciba-Geigy Corporation
    Inventors: Winfried S. Wels, Nancy E. Hynes, Ina-Maria Harweth, Bernd Groner, Norman Hardman, Markus Zwickl